A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High-Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathy - OMS721-HCT-002

Omeros Corp.0 个研究点目标入组 18 人开始时间: 2024年5月23日最近更新: 2024年7月22日

试验速览

阶段: 1 期
状态: 招募中
发起方: Omeros Corp.
入组人数: 18

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 17（—）
性别: All

入选标准

•Age at least 28 days and less than 18 years prior to informed consent (Visit 0)., Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal age of majority., Assent from patients as required by local law and regulation., Have received an allogeneic haematopoietic stem cell transplant for the treatment of non-malignant or malignant disease. All donor cell sources are allowed (i.e., matched, mismatched, and haploidentical; related and unrelated; bone marrow, peripheral blood stem cells, and umbilical cord blood)., Have a diagnosis of high-risk HSCT-TMA, defined as having both of the following: • Platelet count < 50,000/µL or a decrease in platelet count > 50% from the highest value obtained following transplant • Evidence of microangiopathic hemolysis (presence of schistocytes, serum LDH > ULN, or haptoglobin < lower limit of normal [LLN]), Have at least one of the following HSCT-TMA high-risk criteria: • HSCT-TMA persistence = 2 weeks following modification of calcineurin inhibitors or sirolimus OR • Have evidence of high-risk HSCT-TMA defined as at least one of the following: - Spot protein/creatinine ratio = 2 mg/mg - Serum creatinine > 1.5 x the creatinine level prior to TMA development - Biopsy-proven gastrointestinal TMA - TMA-related neurological abnormality (e.g., confusion, stroke, transient ischemic attack [TIA], or seizures) - Pericardial or pleural effusion without alternative explanation - Pulmonary hypertension without alternative explanation - Have Grade III or Grade IV GVHD or, in the opinion of the Investigator, risk for development of Grade III or Grade IV GVHD if immunosuppression were to be modified - Have elevated serum C5b-9 (> 244 ng/mL), If sexually active and of childbearing potential (for female paediatric patients, defined as starting at onset of menses), must agree to practice a highly effective method of birth control throughout the study drug treatment and for at least 12 weeks after the last dose of study drug, such method of birth control defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence (abstinence is acceptable when it is in line with the patient’s preferred and usual lifestyle and is defined as complete abstinence of sexual intercourse, not periodic abstinence or withdrawal), or vasectomized partner., Male patients must be willing to avoid fathering children for at least 12 weeks following the last dose of study medication.

排除标准

•All treatments for HSCT-TMA are allowed except eculizumab, ravulizumab, and defibrotide within 3 months prior to informed consent, unless failure of therapy can be documented. a. Patients may not be on eculizumab, ravulizumab, or defibrotide for any indication at screening., Have a positive test by antigen, antibody, or polymerase chain reaction (PRC) for human immunodeficiency virus (HIV); if negative within 28 days prior to informed consent, the test does not need to be repeated., Patients or their parent or legal guardian who are an employee of Omeros, Clinical Research Organization (CRO), an Investigator, a study staff member, or an immediate family member., Have a known hypersensitivity to any constituent of the product., Presence of any condition that the Investigator believes would put the patient at risk., Have Shiga toxin-producing Escherichia coli haemolytic uraemic syndrome (STEC-HUS). Test results obtained within 28 days prior to informed consent may be used., Have ADAMTS13 activity < 10%. Test results obtained within 28 days prior to informed consent may be used., Have a severe, uncontrolled systemic bacterial or fungal infection requiring antimicrobial therapy, or a severe uncontrolled viral infection (as determined by the investigator); prophylactic antimicrobial therapy administered as standard of care is allowed., Have malignant hypertension (blood pressure [BP] > 99th percentile plus 5 mmHg with bilateral hemorrhages or cotton-wool” exudates on fundoscopic examination)., Due to conditions other than HSCT-TMA, have a poor prognosis with a life expectancy of less than 3 months in the opinion of the Investigator., If pregnant, or lactating., Have received treatment with an investigational drug or device within 4 weeks entering study., Have abnormal liver function tests defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times ULN within 28 days prior to informed consent through prior to the first dose.

研究者

发起方

Omeros Corp.

相似试验

招募中

2 期

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Paediatric Patients (28 Days to 18 Y.O.) with High Risk Haematopoietic Stem Cell Transplant Thrombotic Microangiopathythrombotic microangiopathies (TMA)100188651002766510047066

NL-OMON56242Omeros Corporation2

进行中（未招募）

1 期

A Phase 2 Study on Narsoplimab in Paediatric Patients with High Risk Haematopoietic Stem Cell Transplant Thrombotic MicroangiopathyThrombotic microangiopathies following haematopoietic stem cell transplantMedDRA version: 20.0Level: HLGTClassification code 10064477Term: Coagulopathies and bleeding diatheses (excl thrombocytopenic)System Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: PTClassification code 10043645Term: Thrombotic microangiopathySystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 20.0Level: HLTClassification code 10053567Term: CoagulopathiesSystem Organ Class: 10005329 - Blood and lymphatic system disorders

EUCTR2021-002727-38-HUOmeros Corporation18

进行中（未招募）

1 期

EUCTR2021-002727-38-DEOmeros Corporation18

招募中

2 期

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301)lung cancerSmall Cell Lung Cancer

NL-OMON54228Amgen3

进行中（未招募）

1 期

A Phase 2 Study of Tarlatamab in Patients with Small Cell Lung Cancer (SCLC)

EUCTR2021-002566-40-ATAmgen Inc.160